CN
|
EN
Home
Introduction to the 2024 CBIIC
Previous Speakers
News
Organizations
Service
Transportation & Accommodation
Guidance
Contact us
Previous Review
Home
About CBIIC
Previous Speakers
News
Expert
Organizations
Service
Accommodation
Guidance
Contact us
Previous Review
Business Matching Service
Register
Roadshow Application
Onsite Participant Registration
CN
EN
Rare Diseases & Orphan Drugs Forum
Agendas
13:30 - 17:00
罕见病与前沿技术论坛
Rare Diseases and Advanced Technologies Forum
Moderator
张志娟 , 中国医药创新促进会政策研究中心副主任
ZHANG Zhijuan , Deputy Director of Policy Research Center of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
13:30 - 13:40
开场致辞
Welcome Remarks
李林康 国家卫健委罕见病诊疗与保障专家委员会副主任委员兼办公室主任
LI Linkang , Vice Chairman, Expert Committee on Diagnosis, Treatment and Support of Rare Diseases of the National Health Commission
13:40 - 14:10
报告1
Keynote Speech 1
中国罕见病药物临床试验趋势
Trends in Clinical Trials of Rare Diseases in China
韩晓红 北京协和医院临床药理研究中心主任
HAN Xiaohong , Professor, Director, Clinical Pharmacology Research Center,Peking Union Medical College Hospital
14:10 - 14:40
报告2
Keynote Speech 2
新型基因编辑工具的开发与应用
Development and Application of New Gene Editing Tools
陈佳 上海科技大学基因编辑中心主任
CHEN Jia , Director of Gene Editing Center, ShanghaiTech University
14:40 - 15:10
报告3
Keynote Speech 3
欧美监管框架和条例对细胞基因治疗发展的影响
The Impact of EU/US Regulatory Framework on CGT Development
赵圆 江苏谱新生物医药有限公司首席技术官、欧洲医药监管局(EMA)专家、英国卫生部药品和保健品监督管理局(MHRA)基因治疗部前主任
ZHAO Yuan , Chief Technology Officer of Jiangsu Hillgene
15:10 - 15:40
报告4
Keynote Speech 4
罕见病药物研发转化新生态
New Ecology of Transformation on Rare Diseases Drug R&D
苏明明 武田制药新产品发展部负责人
Val SU , Head of New Product Development, Takeda China
15:40 - 16:10
报告5
Keynote Speech 5
中国罕见病药物研发的探索与思考
China Rare Disease New Drug Development Challenge and Thinking
张苒 北海康成药政事务高级副总裁
Rebecca ZHANG , Senior Vice President, Pharmaceutical Affairs, Canbridge Pharma
16:10 - 17:00
讨论
Panel
支持罕见病药物“中国新”,我们还需要什么?
How to Support China`s Innovative Research and Development in the Field of Rare Diseases
Moderator
刘军帅,国家罕见病诊疗与保障专家委员会委员
LIU Junshuai, Member of Specialty Committee on Diagnosis, Treatment and Protection of Rare Diseases
Panelists
韩晓红,北京协和医院临床药理研究中心主任
HAN Xiaohong,Professor, Director, Clinical Pharmacology Research Center,Peking Union Medical College Hospital
陈佳,上海科技大学基因编辑中心主任
CHEN Jia,Director of Gene Editing Center, ShanghaiTech University
张丹,谱新生物联合创始人、联席董事长
ZHANG Dan,Co-Founder and Co-Chairman of Jiangsu Hillgene
顾琳慧,武田中国新产品发展部副总监
Eileen GU,Associate Director, Takeda China
张苒,北海康成药政事务高级副总裁
Rebecca ZHANG,Senior Vice President, Pharmaceutical Affairs, Canbridge Pharma